WCLC 2025 - Posters & ePosters-EP.12.35 Insights on Treatment Experience From Patients With ALK+ NSCLC Treated With 1St-Line Brigatinib, Lorlatinib and Alectinib

EP.12.35 Insights on Treatment Experience From Patients With ALK+ NSCLC Treated With 1St-Line Brigatinib, Lorlatinib and Alectinib

Asset Subtitle

Christopher Danes

Meta Tag

Speaker Christopher Danes

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy